NCT05542121

Brief Summary

In Phase 2, Patients in a community-based setting who have had a stroke will be evaluated by rehabilitation professionals and asked to perform a battery of clinical assessments before and after standard of care and robot assisted therapy with Rehab CARES system of simple force-feedback robots that are adapted to deliver single and group therapy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
27

participants targeted

Target at P25-P50 for not_applicable stroke

Timeline
Completed

Started Jun 2022

Typical duration for not_applicable stroke

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2022

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

September 6, 2022

Completed
9 days until next milestone

First Posted

Study publicly available on registry

September 15, 2022

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 30, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 30, 2025

Completed
Last Updated

January 7, 2026

Status Verified

January 1, 2026

Enrollment Period

3.2 years

First QC Date

September 6, 2022

Last Update Submit

January 5, 2026

Conditions

Outcome Measures

Primary Outcomes (7)

  • Change in Motor Control

    Measured by Change in Upper Extremity Fugl-Meyer Assessment (UE-FM); scale is out of 66. A lower score means more impaired.

    After 12 sessions (post-pre), after follow-up at 4 weeks (post-follow-up)

  • Change in Gross Hand Function

    Measured by Changes in Box and Block (BnB) Test; metric # of blocks transferred. A higher score means less impaired.

    After 12 sessions (post-pre), after follow-up at 4 weeks (post-follow-up)

  • Change in Hand Dexterity

    Measured by changes in NIH Toolbox 9-Hole Pegboard Dexterity Test; metric time and # of peg transferred over time. A higher number of pegs means less impaired.

    After 12 sessions (post-pre), after follow-up at 4 weeks (post-follow-up)

  • Upper Extremity Function

    Measured by changes in the Neuro-QoL: Upper Extremity Function - Fine Motor, ADL Short Form. Short form is a self-report on 8 items to assesses fine motor function and activity of daily living in upper arm.

    at pre, at post-intervention (after 12 sessions), at follow-up

  • Quality of life (Participation)

    Measured by changes in the Neuro-QoL: Ability to Participate in Social Role and Activities Short Form.

    at pre, at post-intervention (after 12 sessions), at follow-up

  • Quality of life (Satisfaction)

    Measured by changes in Neuro-QoL Satisfaction with Social Roles and Activities Short Form.

    at pre, at post-intervention (after 12 sessions), at follow-up

  • Motivation

    Measured by the Self-Assessment Manikin (SAM) scale which consist of 3 subscales: enjoyment, engagement, and control. Each subscale is from 0 to 9. For enjoyment and engagement the higher score is the better and for control the lower score is better.

    at pre, at post-intervention (after 12 sessions), at follow-up

Secondary Outcomes (12)

  • Change in Cognition

    After 12 sessions (post-pre), after follow-up at 4 weeks (post-follow-up)

  • Visual Spatial Attention

    at pre, at post-intervention (after 12 sessions), at follow-up

  • Executive Function

    at pre, at post-intervention (after 12 sessions), at follow-up

  • Active Joint Range of Motion (ROM)

    at pre, at post-intervention (after 12 sessions), at follow-up

  • Passive Joint Range of Motion (ROM)

    at pre, at post-intervention (after 12 sessions), at follow-up

  • +7 more secondary outcomes

Study Arms (2)

Standard of Care

PLACEBO COMPARATOR

60 min OT sessions; 3 sessions per week; for 4 weeks;-- augmented Standard therapy - consisting of PT, OT and SLP. Clinical Assessment (B1-pre, B2-post, B3-follow-up#1, B4-follow-up#2).

Other: Standard of Care

Robot-Assisted Therapy with Rehab CARES system

EXPERIMENTAL

60 min sessions; 3 sessions per week; for 4 weeks;----of Upper Limb therapy using 1 or more affordable robots. Robot sessions can be group play and/or single play. Robot Assessment (B1-pre, B2-post, B3-follow-up#1, B4-follow-up#2)

Device: Robot-Assisted Therapy with Rehab CARES system

Interventions

60 min sessions; 3 sessions per week; for 4 weeks; Patients uses 1 or more affordable robots to exercise the UL with adaptive games assessments as OT; standard of care PT and SLP; Subjects' motor and cognitive impairment will be used to set the game and modes. The game parameters will be adjusted according to motor and cognitive impairment of that station's user while the controller will automatically adjust assisting or resisting torques experienced. The 60 minutes will be broken up into 15-minute training intervals.

Robot-Assisted Therapy with Rehab CARES system

60 min sessions; 3 sessions per week; for 4 weeks of OT, PT, and SLP

Standard of Care

Eligibility Criteria

Age55 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 55 and older (based on who is admitted to the CBR site)
  • \>3 months post-stroke
  • Stroke diagnosis
  • Diagnosis of hemiparesis as a result of stroke (verified by radiology data)
  • Motor control score on Upper Extremity Fugl-Meyer scale \> 15 and \< 60;
  • Able to understand and speak
  • Upper arm manual muscle strength scores \>1
  • Pain Scores \< 8 based on NIH Pain Intensity Scale

You may not qualify if:

  • no cerebellum lesions due to stroke
  • severe cognitive function

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Mercy Living Independently for Elders (L.I.F.E) - West Philadelphia

Philadelphia, Pennsylvania, 19145, United States

Location

Penn Medicine Rittenhouse

Philadelphia, Pennsylvania, 19146, United States

Location

MeSH Terms

Conditions

StrokeHemiplegia

Interventions

Standard of Care

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesParalysisNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Quality Indicators, Health CareQuality of Health CareHealth Services AdministrationHealth Care Quality, Access, and Evaluation

Study Officials

  • Michelle J Johnson, PhD

    University of Pennsylvania

    PRINCIPAL INVESTIGATOR
  • Alwyn Johnson, MS

    Recupero Robotics LLC

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 6, 2022

First Posted

September 15, 2022

Study Start

June 1, 2022

Primary Completion

August 30, 2025

Study Completion

August 30, 2025

Last Updated

January 7, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will share

It is a priority of the research team to share primary data collected as a result of this project with other researchers and the National Institute of Health and associated funding agents. Findings will be disseminated within a reasonable time via newsletters sponsored by the institutions involved, peer-reviewed conference papers and journals. All journal papers will be placed on PubMed and made publically accessible. All acknowledgements will clearly define the funding agency and follow guidelines stipulated by the NIH. Copies of all publications will provided promptly. All copyright procedures will comply with the standard of NIH copyright clause. After study completion, de-identified data sets will be available to NIH and to other investigators contingent on the execution of relevant institutional data use agreements.

Shared Documents
STUDY PROTOCOL, ICF
Time Frame
Within 2 years of project end
Access Criteria
Those wishing to see protocol and ICF will need to contact study PI

Locations